Relationship Between Clinical Factors of Lymphoma DLBCL GCB and Non-GCB Subtype with Ki-67 Proliferation Index in Siloam Karawaci Hospital 2014 - 2018

Authors

  • Erna Kristiani Department of Histology, Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia
  • Stephanie Marisca Department of Histology, Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia
  • Tri Ulfatul Qurro Department of Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia
  • Natasya Kweeswara Department of Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia
  • Amos Immanuel Chandra Department of Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia

DOI:

https://doi.org/10.19166/med.v11i1.7365

Keywords:

DLBCL, GCB, Non-GCB, Proliferation index Ki-67, Age, Gender, Location, Stadium

Abstract

Background: Non-Hodgkin large cell B-lymphoma (DLBCL: Diffuse Large B-cell Lymphoma) were classified into two subtypes of Germinal Center B-Cell Like (GCB) and non-Germinal Center B-Cell Like (non-GCB), which GCB has a better prognosis. The Ki-67 antigen is one of the most reliable markers of cell proliferation. This research aims to establish the relationship between proliferation index Ki-67 with DLBCL subtypes and to evaluate the utility of Ki-67 proliferative index as a predictive marker for predicting stages of lymphoma.

Methods: We obtained 60 cases of patient samples DLBCL in Siloam Hospital Lippo Karawaci in 2014-2018. Clinical and pathological data were obtained from medical records. Chi-square methods were used to analyze data.

Result: There were more ‰¤60 years compared to >60 years. In this study, there were more male patients than female patients. lymphoma provided in extranodal were higher than lymphoma in nodal form.

Conclusions: There is a relationship between Ki-67 proliferation index with lymphoma GCB and non-GCB subtypes and stage of lymphoma, which can be used as a predictive factor in predicting the stage of lymphoma.

References

1. Jaffe ES. The 2008 WHO Classification of Lymphomas: Implication For Clinical Practice and Translational Research. American Society Of Hematology 2009;(1):523-531. https://doi.org/10.1182/asheducation-2009.1.523

2. Bakta IM. Hematologi Klinis Ringkas. Jakarta: EGC 2006; h.192-219

3. Reksodiputro H, Irawan C, Harjolukito E, Suzana E, et al. Non-Hodgkin Lymphoma in Jakarta. Indonesian Journal of Cancer 2011;5(3):129-133. http://dx.doi.org/10.33371/ijoc.v5i3.171

4. Jaffe ES. The 2008 WHO Classification of Lymphomas: Implication For Clinical Practice and Translational Research. American Society Of Hematology 2009;523-531. https://doi.org/10.1182/asheducation-2009.1.523

5. Tang YL, Zhou Y, Cheng LL, Su YZ, Wang C Bin. BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma. Oncol Lett. 2017;14(3):3767-73. https://doi.org/10.3892/ol.2017.6577

6. Mozaheb, Zahra. Epidemiology of Lymphoid Malignancy in Asia, Epidemiology Insight, Dr. Maria De Lourdes Ribeiro De Souza Da Cunha (ed.). InTech. 2012. https://doi.org/10.5772/31746

7. Yasmin Bhurgri et al.2005.Increasing Incidence of Non-Hodgkin’s Lymphoma in Karachi 1995-2002.Asian Pacific J Cancer Prev. 2005;6(3): 364-369. https://www.researchgate.net/deref/http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F16236001

8. Mengko SK., Surarso B. Patogenesis Limfoma Non-Hodgkin Extra Nodal Kepala dan. J tht-kl. 2009;2(1):32-47.

9. Youssef M.I, Maghraby H, Youssef E.A, El-Sayed M.M. Expression of Ki 67 in hepatocellular carcinoma induced by diethylnitrosamine in mice and its correlation with histopathological alterations. Journal of Applied Pharmaceutical Science 2012. 2(3): 52-59. http://dx.doi.org/10.7324/JAPS.2012.2309

10. Kramer, E, Herman, O, Frand J, Leibou L, Schreiber L, Vaknine H.2014. Ki67 as Biologic Marker of Basal Cell Carcinoma: A Retrospective Study. IMAJ. 2014;16(4): 229-232. https://www.researchgate.net/deref/http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F24834759

Downloads

Published

2023-07-28

Issue

Vol. 12 No. 3 (2023): June

Section

Clinical Research

License

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.